NO20003107L - FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR - Google Patents

FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR

Info

Publication number
NO20003107L
NO20003107L NO20003107A NO20003107A NO20003107L NO 20003107 L NO20003107 L NO 20003107L NO 20003107 A NO20003107 A NO 20003107A NO 20003107 A NO20003107 A NO 20003107A NO 20003107 L NO20003107 L NO 20003107L
Authority
NO
Norway
Prior art keywords
quantification
reagents
solid phase
phase reactions
fluorine nmr
Prior art date
Application number
NO20003107A
Other languages
English (en)
Other versions
NO20003107D0 (no
Inventor
Vasant K Nagulapalli
Edward Orton
John E Airey
Paul H Krolikowski
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1997/023920 external-priority patent/WO1998029376A1/en
Priority claimed from PCT/US1998/026512 external-priority patent/WO1999031491A1/en
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Publication of NO20003107D0 publication Critical patent/NO20003107D0/no
Publication of NO20003107L publication Critical patent/NO20003107L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20003107A 1997-10-17 2000-06-16 FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR NO20003107L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6231897P 1997-10-17 1997-10-17
US6590297P 1997-11-17 1997-11-17
PCT/US1997/023920 WO1998029376A1 (en) 1996-12-19 1997-12-17 Process for the solid phase synthesis of aldehydes, ketones, oximes, amines and hydroxamic acid compounds
PCT/US1998/026512 WO1999031491A1 (en) 1997-12-17 1998-12-14 Method and reagents for the quantification of solid-phase reactions using fluorine nmr

Publications (2)

Publication Number Publication Date
NO20003107D0 NO20003107D0 (no) 2000-06-16
NO20003107L true NO20003107L (no) 2000-07-26

Family

ID=26742119

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20001962A NO20001962L (no) 1997-10-17 2000-04-14 Terapeutisk anvendelse av kinolinderivater
NO20003107A NO20003107L (no) 1997-10-17 2000-06-16 FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20001962A NO20001962L (no) 1997-10-17 2000-04-14 Terapeutisk anvendelse av kinolinderivater

Country Status (17)

Country Link
US (1) US6376512B1 (no)
EP (1) EP1030665A4 (no)
JP (1) JP2001520193A (no)
KR (1) KR20010024533A (no)
CN (1) CN1302206A (no)
AP (1) AP2000001786A0 (no)
AU (1) AU9696198A (no)
BG (1) BG104432A (no)
BR (1) BR9814087A (no)
CA (1) CA2306825A1 (no)
EA (1) EA200000427A1 (no)
HU (1) HUP0101022A1 (no)
IL (1) IL135673A0 (no)
NO (2) NO20001962L (no)
OA (1) OA11371A (no)
PL (1) PL344977A1 (no)
WO (1) WO1999020275A1 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4598278B2 (ja) 1999-04-28 2010-12-15 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｐａｒ受容体リガンドとしてのジアリール酸誘導体
SK15522001A3 (sk) * 1999-04-28 2002-06-04 Aventis Pharma Deutschland Gmbh Deriváty kyselín s tromi arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
CA2382966A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP2001261654A (ja) * 2000-03-21 2001-09-26 Mitsui Chemicals Inc キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬
AU6118001A (en) * 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
DE60139025D1 (de) 2000-12-28 2009-07-30 Takeda Pharmaceutical Alkansäurederivate, verfahren zu deren herstellung und deren verwendung
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
NZ530051A (en) * 2001-06-12 2006-12-22 Wellstat Therapeutics Corp Polycyclic oxy-aromatic acid derivatives for the treatment of metabolic disorders
JPWO2003016265A1 (ja) * 2001-08-17 2004-12-02 エーザイ株式会社 環状化合物およびｐｐａｒアゴニスト
ES2299702T3 (es) 2002-06-20 2008-06-01 Astrazeneca Ab Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina.
SE0201937D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
PL374860A1 (en) 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
WO2005026134A1 (en) 2003-09-17 2005-03-24 Novartis Ag Organic compounds
JP2007536343A (ja) 2004-05-05 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ Ｐｐａｒアゴニストとしてのフェノキシ酢酸誘導体
EP1745014B1 (en) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
CN100418532C (zh) * 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
ATE529404T1 (de) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc Phenoxyessigsäuren als ppar-delta-aktivatoren
TW200800872A (en) * 2005-09-07 2008-01-01 Plexxikon Inc PPAR active compounds
EA015717B1 (ru) 2005-12-22 2011-10-31 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
US9308198B2 (en) 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
US8410154B2 (en) 2008-04-30 2013-04-02 Wellstat Therapeutics Corporation Tetrazole compounds for reducing uric acid
JP5785940B2 (ja) 2009-06-09 2015-09-30 アブラクシス バイオサイエンス， エルエルシー トリアジン誘導体類及びそれらの治療応用
KR20120026612A (ko) 2009-06-09 2012-03-19 아브락시스 바이오사이언스, 엘엘씨 벤질 치환 트리아진 유도체와 이들의 치료적 용도
AU2010258800B2 (en) 2009-06-09 2013-10-10 Nantbio, Inc. Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
EP2590951B1 (en) 2010-07-09 2015-01-07 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
WO2012007877A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
ES2525581T3 (es) 2010-07-12 2014-12-26 Pfizer Limited Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje
US9096500B2 (en) 2010-07-12 2015-08-04 Pfizer Limited Acyl sulfonamide compounds
WO2012007869A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
WO2012007883A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP3129345B1 (en) * 2014-04-06 2023-03-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof
US20230357159A1 (en) * 2020-08-04 2023-11-09 Precision Bio-Therapeutics S.R.L. Quinoline compounds as selective and/or dual modulators of bile acid receptors and leukotriene cysteinyl receptors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US4920130A (en) * 1987-11-02 1990-04-24 Rorer Pharamceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
AU683114B2 (en) * 1993-11-29 1997-10-30 Merrell Pharmaceuticals Inc. Novel benzenesulfonylimine derivatives as inhibitors of IL-1 action
DE69512495T2 (de) * 1994-10-27 2000-02-03 Asahi Glass Co. Ltd., Tokio/Tokyo Verfahren zur Herstellung von Chinolin-2-yl-benzoesäure
PT871439E (pt) * 1996-01-02 2004-08-31 Aventis Pharma Inc Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo)

Also Published As

Publication number Publication date
AU9696198A (en) 1999-05-10
HUP0101022A1 (hu) 2001-10-28
AP2000001786A0 (en) 2000-04-16
EP1030665A1 (en) 2000-08-30
IL135673A0 (en) 2001-05-20
OA11371A (en) 2004-01-28
CA2306825A1 (en) 1999-04-29
NO20001962L (no) 2000-06-16
BR9814087A (pt) 2000-10-03
NO20003107D0 (no) 2000-06-16
EP1030665A4 (en) 2002-11-27
PL344977A1 (en) 2001-11-19
CN1302206A (zh) 2001-07-04
BG104432A (bg) 2000-12-29
KR20010024533A (ko) 2001-03-26
NO20001962D0 (no) 2000-04-14
EA200000427A1 (ru) 2001-02-26
US6376512B1 (en) 2002-04-23
WO1999020275A1 (en) 1999-04-29
JP2001520193A (ja) 2001-10-30

Similar Documents

Publication Publication Date Title
NO20003107L (no) FremgangsmÕte og reagenter for kvantifisering av fastfasereaksjoner ved bruk av fluor NMR
NO981360L (no) Fremgangsmåte til sammenföyning av metalliske sammenföyningselementer ved hjelp av friksjonsagitasjon
NO955113L (no) Anordning og fremgangsmåte ved endostern reaksjon
DK0811128T3 (da) Fremgangsmåde til at forbinde forede røremner og røremner forbundet ved denne fremgangsmåde
EP0914349A4 (en) SYNTHESIZER WITH MULTIPLE REACTORS AND METHOD OF COMBINATORY CHEMISTRY
EP0864090A4 (en) METHOD AND APPARATUS FOR QUANTITATIVE AND SEMI-QUANTITATIVE EVALUATION OF A SUBSTANCE TO BE ANALYZED
AU1400099A (en) High-throughput method and apparatus for identifying, quantitating and determining the purity of chemical compounds in mixtures
EP0709769A3 (en) Apparatus and method for analysis and resolution of operand dependencies
DK1015662T3 (da) Fremgangsmåde til forebyggelse af korrosion af metaller ved anvendelse af silaner
BR9708036A (pt) Processo para a análise de um analito e e aparelho analitico
EP1051583A4 (en) METHOD AND DEVICE FOR OPTICAL IMPROVEMENT OF CHEMICAL REACTIONS
AU6215800A (en) Method and apparatus for rapid screening of multiphase reactions
NO983957D0 (no) Fremgangsmåte ved sammenföyning av tofase rustfritt stål
NO20002075L (no) FremgangsmÕte ved aminering
DK1034396T3 (da) Fremgangsmåde og apparat til afskibning af superfrosne materialer
AU2001265351A1 (en) Method and analytical system for rapid screening of combinatorial libraries
NO952246L (no) Fremgangsmåte ved installasjon av strekkstagplattform
DE69806950D1 (de) Neues reaktionsgefäss und verfahren zu dessen verwendung
FR2805044B1 (fr) Procede et dispositif de determination de l'evolution d'une reaction chimique dans un four et de reglage de la reaction
BR9405079A (pt) Produto químico antiamebiano e antiprotozário e processo para sua obtenção
NO960401L (no) Fremgangsmåte ved fristempelinnretninger og anordning til utförelse av fremgangsmåten
HUP0200726A2 (en) Method and reagents for the quantification of solid-phase reactions using fluorine nmr
HK1033357A1 (en) Method for the quantification of solid-phase reactions using fluorine nmr
ID24281A (id) Metoda pembakaran suatu reaksi kimia secara induksi
NO20000182D0 (no) Fremgangsmåte for fremstilling av alkoksyfuranonaminderivater, forbindelser frembragt ved fremgangsmåten og anvendelse av disse forbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application